OSAnalyzer

OSAnalyzer analyzes overall survival (OS) and progression-free survival (PFS) in cancer patients and correlates these outcomes with ADME gene variants profiled by Affymetrix DMET microarrays.

Key Features:

• Survival Analysis: Computes overall survival (OS) and progression-free survival (PFS) distributions for cancer patient cohorts.
• ADME Gene Variant Evaluation: Assesses associations between ADME gene variants and survival outcomes using DMET microarray profiles.
• Automated Data Processing: Performs automatic analysis of Affymetrix DMET data enriched with clinical survival events.
• Statistical Significance Ranking: Ranks results based on statistical significance using the area under the curves computed by the log-rank test.
• Visualization Capabilities: Generates visual representations of survival analysis results.

Scientific Applications:

• Biomarker discovery: Identification of ADME-related genetic biomarkers associated with patient survival.
• Pharmacogenomics: Exploration of how genetic variation in drug metabolism and excretion influences efficacy and toxicity in cancer treatments.
• Personalized oncology: Support for correlating patient genetic profiles with survival outcomes to inform genotype-guided treatment hypotheses.

Methodology:

Processes Affymetrix DMET microarray genetic data alongside clinical survival data and applies the log-rank test, including computation of area under the curves, to assess and rank differences in survival distributions.